Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients

Ustekinumab (UST) is approved for the treatment of moderate and severe Crohn disease (CD). Therapeutic drug monitoring (TDM) can help monitor the therapeutic effects of biologics. Therefore, the aim of this study was to evaluate the clinical outcomes of UST-treated CD patients and to determine the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Mechie, Nicolae-Catalin, Burmester, Merle, Mavropoulou, Eirini, Pilavakis, Yiannis, Kunsch, Steffen, Ellenrieder, Volker, Amanzada, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982165/
https://www.ncbi.nlm.nih.gov/pubmed/33725990
http://dx.doi.org/10.1097/MD.0000000000025111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982165/
https://www.ncbi.nlm.nih.gov/pubmed/33725990
http://dx.doi.org/10.1097/MD.0000000000025111

Ejemplares similares